New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareKPV vs Retatrutide

KPV vs Retatrutide

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
KPV
GLP-1 / Weight Loss Agonists
Retatrutide
Summary
KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Half-Life
Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
~10–12 days
Admin Route
Oral, SubQ, Topical
SubQ
Research
Typical Dose
500 mcg – 1 mg
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
Frequency
Once to twice daily
Once weekly
Key Benefits
  • Reduces intestinal inflammation (IBD, Crohn's, colitis)
  • Promotes gut mucosal healing and barrier integrity
  • Accelerates wound healing topically
  • Suppresses systemic inflammatory cytokines
  • Antimicrobial properties against pathogens
  • Reduces neuroinflammation when administered systemically
  • May improve symptoms of inflammatory skin conditions
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
Side Effects
  • Generally very well tolerated
  • Mild injection site reactions (SC)
  • Rare: transient flushing
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
Stacks With